A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours

Histopathology

Volumn 62, Issue 1, 2013, Pages 71-88

  Rabban, Joseph T ^a   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Germ cell tumour; Immunohistochemistry; Sex cord stromal tumour

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA FETOPROTEIN; CALRETININ; CD56 ANTIGEN; CHORIONIC GONADOTROPIN; CHROMOGRANIN; CYTOKERATIN 18; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN AE1; CYTOKERATIN AE3; ESTROGEN RECEPTOR; GLYPICAN 3; INHIBIN; MELAN A; OCTAMER TRANSCRIPTION FACTOR 4; PODOPLANIN; PROGESTERONE RECEPTOR; SALL4 PROTEIN; STEM CELL FACTOR RECEPTOR; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANDROBLASTOMA; ARTICLE; CELL DIFFERENTIATION; CHORIOCARCINOMA; CLEAR CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DYSGERMINOMA; EMBRYONAL CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GERM CELL TUMOR; GONADOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LEYDIG CELL; OVARY TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SEX CORD TUMOR; TERATOMA; TUMOR DIFFERENTIATION; YOLK SAC TUMOR;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; SEX CORD-GONADAL STROMAL TUMORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871153761     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12052     Document Type: Article

References (151)

1. Niehans GA, Manivel JC, Copland GT, Scheithauer BW, Wick MR. Immunohistochemistry of germ cell and trophoblastic neoplasms. Cancer 1988; 62; 1113-1123.
2. Lifschitz-Mercer B, Walt H, Kushnir I et al. Differentiation potential of ovarian dysgerminoma: an immunohistochemical study of 15 cases. Hum. Pathol. 1995; 26; 62-66.
3. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De ME, Lothe RA. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol. Cancer 2007; 6; 12.
4. Bollinger DJ, Wick MR, Dehner LP, Mills SE, Swanson PE, Clarke RE. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison. Am. J. Surg. Pathol. 1989; 13; 659-670.
5. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am. J. Surg. Pathol. 1998; 22; 1203-1214.
6. Wick MR, Swanson PE, Manivel JC. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum. Pathol. 1987; 18; 946-954.
7. Cao D, Guo S, Allan RW, Molberg KH, Peng Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am. J. Surg. Pathol. 2009; 33; 894-904.
8. Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. Cancer 2009; 115; 2640-2651.
9. Cao D, Li J, Guo CC, Allan RW, Humphrey PA. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am. J. Surg. Pathol. 2009; 33; 1065-1077.
10. Cao D, Liu A, Wang F et al. RNA-binding protein LIN28 is a marker for primary extragonadal germ cell tumors: an immunohistochemical study of 131 cases. Mod. Pathol. 2011; 24; 288-296.
11. Liu A, Cheng L, Du J et al. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am. J. Surg. Pathol. 2010; 34; 697-706.
12. Mei K, Liu A, Allan RW et al. Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod. Pathol. 2009; 22; 1628-1636.
13. Wang F, Liu A, Peng Y et al. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am. J. Surg. Pathol. 2009; 33; 1529-1539.
14. Bai S, Wei S, Ziober A, Yao Y, Bing Z. SALL4 and SF-1 are sensitive and specific markers for distinguishing granulosa cell tumors from yolk sac tumors. Int. J. Surg. Pathol. 25 July 2012 [Epub ahead of print].
15. Ikeda H, Sato Y, Yoneda N et al. alpha-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. Hum. Pathol. 2012; 43; 1955-1963.
16. Ushiku T, Shinozaki A, Shibahara J et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am. J. Surg. Pathol. 2010; 34; 533-540.
17. Low JJ, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumours. Best Pract. Res. Clin. Obstet. Gynaecol. 2012; 26; 347-355.
18. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat. Rev. 2008; 34; 427-441.
19. Looijenga LH, Stoop H, de Leeuw HP et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003; 63; 2244-2250.
20. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW. OCT4: a novel biomarker for dysgerminoma of the ovary. Am. J. Surg. Pathol. 2004; 28; 1341-1346.
21. Kao CS, Idrees MT, Young RH, Ulbright TM. Solid pattern yolk sac tumor: a morphologic and immunohistochemical study of 52 cases. Am. J. Surg. Pathol. 2012; 36; 360-367.
22. Chang MC, Vargas SO, Hornick JL, Hirsch MS, Crum CP, Nucci MR. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int. J. Gynecol. Pathol. 2009; 28; 347-355.
23. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004; 101; 2006-2010.
24. Cheng L, Roth LM, Zhang S et al. KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer 2011; 117; 2096-2103.
25. Sever M, Jones TD, Roth LM et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod. Pathol. 2005; 18; 1411-1416.
26. Jin ZW, Kim YG, Yu HC, Murakami G, Fujimiya M, Cho BH. A comparison between D2-40 and c-KIT immunohistochemistry for the human fetal testis and ovary at the second trimester of gestation. Okajimas Folia Anat. Jpn. 2010; 87; 1-4.
27. Schmandt RE, Broaddus R, Lu KH et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003; 98; 758-764.
28. Irving JA, Lerwill MF, Young RH. Gastrointestinal stromal tumors metastatic to the ovary: a report of five cases. Am. J. Surg. Pathol. 2005; 29; 920-926.
29. McCluggage WG, Bissonnette JP, Young RH. Primary malignant melanoma of the ovary: a report of 9 definite or probable cases with emphasis on their morphologic diversity and mimicry of other primary and secondary ovarian neoplasms. Int. J. Gynecol. Pathol. 2006; 25; 321-329.
30. Tate G, Tajiri T, Suzuki T, Mitsuya T. Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary. Cancer Genet. Cytogenet. 2009; 190; 15-20.
31. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am. J. Pathol. 2005; 166; 913-921.
32. Idrees M, Saxena R, Cheng L, Ulbright TM, Badve S. Podoplanin, a novel marker for seminoma: a comparison study evaluating immunohistochemical expression of podoplanin and OCT3/4. Ann. Diagn. Pathol. 2010; 14; 331-336.
33. Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod. Pathol. 2007; 20; 320-325.
34. Iczkowski KA, Butler SL, Shanks JH et al. Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum. Pathol. 2008; 39; 275-281.
35. Yu H, Pinkus GS, Hornick JL. Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Am. J. Clin. Pathol. 2007; 128; 767-775.
36. Kalof AN, Cooper K. D2-40 immunohistochemistry-so far! Adv. Anat. Pathol. 2009; 16; 62-64.
37. Ordonez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv. Anat. Pathol. 2006; 13; 83-88.
38. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 2005; 36; 372-380.
39. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod. Pathol. 2006; 19; 34-48.
40. Emerson RE, Ulbright TM. Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. Pathology 2010; 42; 344-355.
41. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005; 104; 2255-2265.
42. Gillis AJ, Stoop H, Biermann K et al. Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis. Int. J. Androl. 2011; 34; e160-e174.
43. Hart AH, Hartley L, Parker K et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005; 104; 2092-2098.
44. Hoei-Hansen CE, Almstrup K, Nielsen JE et al. Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology 2005; 47; 48-56.
45. Santagata S, Hornick JL, Ligon KL. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am. J. Surg. Pathol. 2006; 30; 1613-1618.
46. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am. J. Surg. Pathol. 2007; 31; 836-845.
47. Cossu-Rocca P, Jones TD, Roth LM et al. Cytokeratin and CD30 expression in dysgerminoma. Hum. Pathol. 2006; 37; 1015-1021.
48. Zaloudek CJ, Tavassoli FA, Norris HJ. Dysgerminoma with syncytiotrophoblastic giant cells. A histologically and clinically distinctive subtype of dysgerminoma. Am. J. Surg. Pathol. 1981; 5; 361-367.
49. Kurman RJ, Norris HJ. Embryonal carcinoma of the ovary: a clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer 1976; 38; 2420-2433.
50. Kurman RJ, Norris HJ. Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet. Gynecol. 1976; 48; 579-589.
51. Ueda G, Abe Y, Yoshida M, Fujiwara T. Embryonal carcinoma of the ovary: a six-year survival. Int. J. Gynaecol. Obstet. 1990; 31; 287-292.
52. Cheng L, Zhang S, Talerman A, Roth LM. Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma. Hum. Pathol. 2010; 41; 716-723.
53. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am. J. Surg. Pathol. 2004; 28; 935-940.
54. Sung MT, Jones TD, Beck SD, Foster RS, Cheng L. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum. Pathol. 2006; 37; 662-667.
55. Durkop H, Foss HD, Eitelbach F et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J. Pathol. 2000; 190; 613-618.
56. Gopalan A, Dhall D, Olgac S et al. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod. Pathol. 2009; 22; 1066-1074.
57. Latza U, Foss HD, Durkop H et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am. J. Pathol. 1995; 146; 463-471.
58. Leroy X, Augusto D, Leteurtre E, Gosselin B. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J. Histochem. Cytochem. 2002; 50; 283-285.
59. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am. J. Pathol. 1988; 133; 446-450.
60. Suster S, Moran CA, Dominguez-Malagon H, Quevedo-Blanco P. Germ cell tumors of the mediastinum and testis: a comparative immunohistochemical study of 120 cases. Hum. Pathol. 1998; 29; 737-742.
61. Berney DM, Shamash J, Pieroni K, Oliver RT. Loss of CD30 expression in metastatic embryonal carcinoma: the effects of chemotherapy? Histopathology 2001; 39; 382-385.
62. Miller JS, Lee TK, Epstein JI, Ulbright TM. The utility of microscopic findings and immunohistochemistry in the classification of necrotic testicular tumors: a study of 11 cases. Am. J. Surg. Pathol. 2009; 33; 1293-1298.
63. Harms D, Janig U. Germ cell tumours of childhood. Report of 170 cases including 59 pure and partial yolk-sac tumours. Virchows Arch. A Pathol. Anat. Histopathol. 1986; 409; 223-239.
64. Clement PB, Young RH, Scully RE. Endometrioid-like variant of ovarian yolk sac tumor. A clinicopathological analysis of eight cases. Am. J. Surg. Pathol. 1987; 11; 767-778.
65. Prat J, Bhan AK, Dickersin GR, Robboy SJ, Scully RE. Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation): a light microscopic, ultrastructural and immunohistochemical study of seven cases. Cancer 1982; 50; 2355-2368.
66. Devouassoux-Shisheboran M, Schammel DP, Tavassoli FA. Ovarian hepatoid yolk sac tumours: morphological, immunohistochemical and ultrastructural features. Histopathology 1999; 34; 462-469.
67. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am. J. Surg. Pathol. 2008; 32; 600-607.
68. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976; 38; 2404-2419.
69. Zirker TA, Silva EG, Morris M, Ordonez NG. Immunohistochemical differentiation of clear-cell carcinoma of the female genital tract and endodermal sinus tumor with the use of alpha-fetoprotein and Leu-M1. Am. J. Clin. Pathol. 1989; 91; 511-514.
70. Ramalingam P, Malpica A, Silva EG, Gershenson DM, Liu JL, Deavers MT. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am. J. Surg. Pathol. 2004; 28; 1499-1505.
71. Furumoto M. Cellular localization of AFP, hCG and its free subunits, and SP1 in embryonal carcinoma of the testis and ovary. Pathol. Res. Pract. 1981; 173; 12-21.
72. Nakashima N, Fukatsu T, Nagasaka T, Sobue M, Takeuchi J. The frequency and histology of hepatic tissue in germ cell tumors. Am. J. Surg. Pathol. 1987; 11; 682-692.
73. Perrone T, Steeper TA, Dehner LP. Alpha-fetoprotein localization in pure ovarian teratoma. An immunohistochemical study of 12 cases. Am. J. Clin. Pathol. 1987; 88; 713-717.
74. Gagnon S, Tetu B, Silva EG, McCaughey WT. Frequency of alpha-fetoprotein production by Sertoli-Leydig cell tumors of the ovary: an immunohistochemical study of eight cases. Mod. Pathol. 1989; 2; 63-67.
75. Hammad A, Jasnosz KM, Olson PR. Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Arch. Pathol. Lab. Med. 1995; 119; 1075-1079.
76. Ishikura H, Scully RE. Hepatoid carcinoma of the ovary. A newly described tumor. Cancer 1987; 60; 2775-2784.
77. Mooney EE, Nogales FF, Tavassoli FA. Hepatocytic differentiation in retiform Sertoli-Leydig cell tumors: distinguishing a heterologous element from Leydig cells. Hum. Pathol. 1999; 30; 611-617.
78. Pitman MB, Triratanachat S, Young RH, Oliva E. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma. Int. J. Gynecol. Pathol. 2004; 23; 58-64.
79. Tochigi N, Kishimoto T, Supriatna Y, Nagai Y, Nikaido T, Ishikura H. Hepatoid carcinoma of the ovary: a report of three cases admixed with a common surface epithelial carcinoma. Int. J. Gynecol. Pathol. 2003; 22; 266-271.
80. Young RH, Gersell DJ, Clement PB, Scully RE. Hepatocellular carcinoma metastatic to the ovary: a report of three cases discovered during life with discussion of the differential diagnosis of hepatoid tumors of the ovary. Hum. Pathol. 1992; 23; 574-580.
81. Maeda D, Ota S, Takazawa Y et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod. Pathol. 2009; 22; 824-832.
82. Pantanowitz L, Otis CN. Glypican-3 immunohistochemistry in the ovary. Histopathology 2008; 53; 115-117.
83. Zynger DL, McCallum JC, Luan C, Chou PM, Yang XJ. Glypican 3 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns. Histopathology 2010; 56; 750-757.
84. Ota S, Hishinuma M, Yamauchi N et al. Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 2006; 449; 308-314.
85. Umezu T, Shibata K, Kajiyama H, Yamamoto E, Nawa A, Kikkawa F. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. J. Clin. Pathol. 2010; 63; 962-966.
86. Libbrecht L, Severi T, Cassiman D et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol. 2006; 30; 1405-1411.
87. Wang XY, Degos F, Dubois S et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum. Pathol. 2006; 37; 1435-1441.
88. Yamauchi N, Watanabe A, Hishinuma M et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod. Pathol. 2005; 18; 1591-1598.
89. Zhao C, Bratthauer GL, Barner R, Vang R. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: a study of 160 cases. Am. J. Surg. Pathol. 2007; 31; 255-266.
90. Rabban JT, Lerwill MF, McCluggage WG, Grenert JP, Zaloudek CJ. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. Int. J. Gynecol. Pathol. 2009; 28; 41-48.
91. Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 407-414.
92. Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am. J. Surg. Pathol. 2009; 33; 626-632.
93. Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum. Pathol. 2001; 32; 1087-1093.
94. Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am. J. Surg. Pathol. 2001; 25; 815-819.
95. Saqi A, Alexis D, Remotti F, Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am. J. Clin. Pathol. 2005; 123; 394-404.
96. Kubba LA, McCluggage WG, Liu J et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod. Pathol. 2008; 21; 485-490.
97. Zhang PJ, Gao HG, Pasha TL, Litzky L, LiVolsi VA. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int. J. Gynecol. Pathol. 2009; 28; 10-18.
98. Ozcan A, Shen SS, Hamilton C et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod. Pathol. 2011; 24; 751-764.
99. Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am. J. Surg. Pathol. 2010; 34; 723-729.
100. Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod. Pathol. 2011; 24; 412-424.
101. Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod. Pathol. 2012; 25; 893-901.
102. Guerrieri C, Franlund B, Malmstrom H, Boeryd B. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: a study using inhibin and cytokeratin 7. Int. J. Gynecol. Pathol. 1998; 17; 266-271.
103. Ordi J, Schammel DP, Rasekh L, Tavassoli FA. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases. Mod. Pathol. 1999; 12; 933-940.
104. Roth LM, Liban E, Czernobilsky B. Ovarian endometrioid tumors mimicking Sertoli and Sertoli-Leydig cell tumors: sertoliform variant of endometrioid carcinoma. Cancer 1982; 50; 1322-1331.
105. Aguirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. An immunohistochemical study. Int. J. Gynecol. Pathol. 1989; 8; 364-373.
106. Young RH, Prat J, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. A clinicopathological analysis of 13 cases. Am. J. Surg. Pathol. 1982; 6; 513-522.
107. Zhao C, Barner R, Vinh TN, McManus K, Dabbs D, Vang R. SF-1 is a diagnostically useful immunohistochemical marker and comparable to other sex cord-stromal tumor markers for the differential diagnosis of ovarian sertoli cell tumor. Int. J. Gynecol. Pathol. 2008; 27; 507-514.
108. Al-Agha OM, Huwait HF, Chow C et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am. J. Surg. Pathol. 2011; 35; 484-494.
109. Cao QJ, Jones JG, Li M. Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors. Int. J. Gynecol. Pathol. 2001; 20; 346-352.
110. Kommoss F, Oliva E, Bhan AK, Young RH, Scully RE. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod. Pathol. 1998; 11; 656-664.
111. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum. Pathol. 1998; 29; 840-845.
112. Costa MJ, Ames PF, Walls J, Roth LM. Inhibin immunohistochemistry applied to ovarian neoplasms: a novel, effective, diagnostic tool. Hum. Pathol. 1997; 28; 1247-1254.
113. Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod. Pathol. 2003; 16; 584-590.
114. McCluggage WG, Maxwell P. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology 2001; 38; 403-408.
115. Riopel MA, Perlman EJ, Seidman JD, Kurman RJ, Sherman ME. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int. J. Gynecol. Pathol. 1998; 17; 46-53.
116. Shah VI, Freites ON, Maxwell P, McCluggage WG. Inhibin is more specific than calretinin as an immunohistochemical marker for differentiating sarcomatoid granulosa cell tumour of the ovary from other spindle cell neoplasms. J. Clin. Pathol. 2003; 56; 221-224.
117. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am. J. Surg. Pathol. 2002; 26; 1477-1483.
118. Zhao C, Vinh TN, McManus K, Dabbs D, Barner R, Vang R. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am. J. Surg. Pathol. 2009; 33; 354-366.
119. Bakke M, Zhao L, Hanley NA, Parker KL. Approaches to define the role of SF-1 at different levels of the hypothalamic-pituitary-steroidogenic organ axis. Endocr. Res. 2000; 26; 1067-1073.
120. Bakke M, Zhao L, Hanley NA, Parker KL. SF-1: a critical mediator of steroidogenesis. Mol. Cell. Endocrinol. 2001; 171; 5-7.
121. Ozisik G, Achermann JC, Jameson JL. The role of SF1 in adrenal and reproductive function: insight from naturally occurring mutations in humans. Mol. Genet. Metab. 2002; 76; 85-91.
122. Hanley NA, Ikeda Y, Luo X, Parker KL. Steroidogenic factor 1 (SF-1) is essential for ovarian development and function. Mol. Cell. Endocrinol. 2000; 163; 27-32.
123. Hanley NA, Ball SG, Clement-Jones M et al. Expression of steroidogenic factor 1 and Wilms' tumour 1 during early human gonadal development and sex determination. Mech. Dev. 1999; 87; 175-180.
124. Sasano H, Kaga K, Sato S, Yajima A, Nagura H. Adrenal 4-binding protein in common epithelial and metastatic tumors of the ovary. Hum. Pathol. 1996; 27; 595-598.
125. Enriquez ML, Lal P, Ziober A, Wang L, Tomaszewski JE, Bing Z. The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 141-145.
126. Sangoi AR, Fujiwara M, West RB et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am. J. Surg. Pathol. 2011; 35; 678-686.
127. Sangoi AR, McKenney JK. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am. J. Surg. Pathol. 2010; 34; 423-432.
128. D'Angelo E, Mozos A, Nakayama D et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod. Pathol. 2011; 24; 1360-1367.
129. Kim MS, Hur SY, Yoo NJ, Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J. Pathol. 2010; 221; 147-152.
130. Schmidt D, Ovitt CE, Anlag K et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 2004; 131; 933-942.
131. Jamieson S, Butzow R, Andersson N et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod. Pathol. 2010; 23; 1477-1485.
132. Kim T, Sung CO, Song SY, Bae DS, Choi YL. FOXL2 mutation in granulosa-cell tumours of the ovary. Histopathology 2010; 56; 408-410.
133. Shah SP, Kobel M, Senz J et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 2009; 360; 2719-2729.
134. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum. Pathol. 2005; 36; 195-201.
135. Barcena C, Oliva E. WT1 expression in the female genital tract. Adv. Anat. Pathol. 2011; 18; 454-465.
136. Costa MJ, DeRose PB, Roth LM, Brescia RJ, Zaloudek CJ, Cohen C. Immunohistochemical phenotype of ovarian granulosa cell tumors: absence of epithelial membrane antigen has diagnostic value. Hum. Pathol. 1994; 25; 60-66.
137. McCluggage WG, McKenna M, McBride HA. CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors. Int. J. Gynecol. Pathol. 2007; 26; 322-327.
138. Ohishi Y, Kaku T, Oya M, Kobayashi H, Wake N, Tsuneyoshi M. CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol. Oncol. 2007; 107; 30-38.
139. Farinola MA, Gown AM, Judson K et al. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int. J. Gynecol. Pathol. 2007; 26; 375-382.
140. Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am. J. Surg. Pathol. 2005; 29; 143-156.
141. Zhao C, Bratthauer GL, Barner R, Vang R. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor. Am. J. Surg. Pathol. 2007; 31; 1378-1386.
142. Young RH, Prat J, Scully RE. Ovarian Sertoli-Leydig cell tumors with heterologous elements. I. Gastrointestinal epithelium and carcinoid: a clinicopathologic analysis of thirty-six cases. Cancer 1982; 50; 2448-2456.
143. Aguirre P, Scully RE, Delellis RA. Ovarian heterologous Sertoli-Leydig cell tumors with gastrointestinal-type epithelium. An immunohistochemical analysis. Arch. Pathol. Lab. Med. 1986; 110; 528-533.
144. Prat J, Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors with heterologous elements. II. Cartilage and skeletal muscle: a clinicopathologic analysis of twelve cases. Cancer 1982; 50; 2465-2475.
145. Jones MW, Harri R, Dabbs DJ, Carter GJ. Immunohistochemical profile of steroid cell tumor of the ovary: a study of 14 cases and a review of the literature. Int. J. Gynecol. Pathol. 2010; 29; 315-320.
146. Rishi M, Howard LN, Bratthauer GL, Tavassoli FA. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am. J. Surg. Pathol. 1997; 21; 583-589.
147. Deavers MT, Malpica A, Ordonez NG, Silva EG. Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin. Int. J. Gynecol. Pathol. 2003; 22; 162-167.
148. Prasad CJ, Silva EG, Welch WR. Immunohistochemical characteristics of steroid cell tumors of the ovary. Mod. Pathol. 1994; 7; 94A.
149. Seidman JD, Abbondanzo SL, Bratthauer GL. Lipid cell (steroid cell) tumor of the ovary: immunophenotype with analysis of potential pitfall due to endogenous biotin-like activity. Int. J. Gynecol. Pathol. 1995; 14; 331-338.
150. Oliva E, Garcia-Miralles N, Vu Q, Young RH. CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases. Int. J. Gynecol. Pathol. 2007; 26; 359-367.
151. Vang R, Herrmann ME, Tavassoli FA. Comparative immunohistochemical analysis of granulosa and sertoli components in ovarian sex cord-stromal tumors with mixed differentiation: potential implications for derivation of sertoli differentiation in ovarian tumors. Int. J. Gynecol. Pathol. 2004; 23; 151-161.